[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@intimepk Avatar @intimepk Peter

Peter posts on X about $qure, $mreo, $glsi, $mdnaf the most. They currently have XX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social topic influence $qure, $mreo, $glsi, $mdnaf, $fip, $vltlf, $dlo, $ftai, $glng, $tmdx

Top assets mentioned DLocal Limited Class A Common Shares (DLO) Fortress Transportation and Infrastructure Investors LLC Class A Common Stock (FTAI) Golar LNG Ltd (GLNG) TransMedics Group, Inc. Common Stock (TMDX) Viking Therapeutics, Inc (VKTX)

Top Social Posts #

Top posts by engagements in the last XX hours

"Current holdings and 6-mo PTs: $DLO 20; $FTAI 180+; $VLTLF 1.00+; $GLNG 70; $FIP 13+; $TMDX 150; $MDNAF 5; $VKTX 70; $GLSI 70; $QURE 70; $MREO 7"
@intimepk Avatar @intimepk on X 2025-07-21 21:35:33 UTC XX followers, 2704 engagements

"$QURE down this morning on $REPL's CRL. I'm not familiar enough with REPL's trial and patient pop/disease. $CAPR also received CRL recently in my opinion on a low N. N for QURE higher than CAPR (though not by much) and without the heterogeneity of REPL's - if you grok the details QURE's is very clean in comparison. Bottom line this CBER is getting tough to read/predict. They roadshow "we don't even need long trials" and then deny breakthrough designated drugs and go against their own guidance"
@intimepk Avatar @intimepk on X 2025-07-22 12:32:57 UTC XX followers, 1261 engagements